C.L. King analyst Kristen Stewart maintains $Boston Scientific (BSX.US)$ with a buy rating, and adjusts the target price from $64 to $90.
According to TipRanks data, the analyst has a success rate of 60.6% and a total average return of 3.5% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Boston Scientific (BSX.US)$'s main analysts recently are as follows:
Boston Scientific has reported a quarter that exceeded expectations on all fronts, despite high expectations. Nonetheless, the company's shares are experiencing pressure due to the announced pause in the AVANT GUARD clinical trial, which is investigating Farapulse in a new patient segment. It is noted that this particular segment is not currently receiving treatment, there are observations under assessment, and the expectation is for enrollment to recommence shortly.
Boston Scientific's Q3 outcomes were deemed impressive, with management raising its 2024 guidance to reflect a departure from the year at +15% organic sales growth. Despite a temporary halt in an EP trial, AVANTGUARD, which led to a decrease in stock value, assessments with key opinion leaders suggest that the reaction may have been exaggerated.
Following Boston Scientific's Q3 report, it was noted that the AVANT Guard trial setback is not associated with a mortality event nor initiated by the FDA, and that momentum for Farapulse globally is expected to be sustainable over the medium term. The recent decline in Boston Scientific's share price is seen as a 'compelling' opportunity for entry.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
CL King分析师Kristen Stewart维持$波士顿科学 (BSX.US)$买入评级，并将目标价从64美元上调至90美元。
根据TipRanks数据显示，该分析师近一年总胜率为60.6%，总平均回报率为3.5%。
此外，综合报道，$波士顿科学 (BSX.US)$近期主要分析师观点如下：
波士顿科学公司报告的季度在各个方面均超出预期，尽管期望值较高。然而，由于宣布暂停 AVANt GUARD 临床试验，该公司的股票正受到压力。该试验旨在研究 Farapulse 在新的患者群体中的应用。值得注意的是，这个特定群体目前未接受治疗，正在进行评估观察，并预计很快将恢复招募。
波士顿科学的第3季度业绩被认为令人印象深刻，管理层调高了2024年指引，以反映年度 +15% 的有机销售增长。尽管心脏电生理试验 AVANTGUARD 暂停，导致股价下降，但主要意见领袖的评估表明，市场反应可能有所夸大。
根据波士顿科学第3季度报告，注意到 AVANt Guard 试验的挫折并非由死亡事件引起，也非 FDA 发起，全球 Farapulse 的动力预计在中期内将是可持续的。波士顿科学股价最近的下跌被视为一个“引人注目”的进入机会。
提示:
TipRanks为独立第三方，提供金融分析师的分析数据，并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议，仅供参考。本文不对评级数据和报告的完整性与准确性做出认可、声明或保证。
TipRanks提供每位分析师的星级，分析师星级代表分析师所有推荐的过往表现，通过分析师的总胜率和平均回报率综合计算得出，星星越多，则该分析师过往表现越优异，最高为5颗星。
分析师总胜率为近一年分析师的评级成功次数占总评级次数的比率。评级的成功与否，取决于TipRanks的虚拟投资组合是否从该股票中产生正回报。
总平均回报率为基于分析师的初始评级创建虚拟投资组合，并根据评级变化对组合进行调整，在近一年中该投资组合所获得的回报率。
